Octagon Capital Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Octagon Capital Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-499,996	Closed	-$8.59M	–	44
2023 Q1	$8.59M	Hold	499,996	–	–	1.24%	16
2022 Q4	$11.1M	Hold	499,996	–	–	1.73%	15
2022 Q3	$4.02M	Sell	499,996 -132,749	-21%	-$1.2M	0.69%	23
2022 Q2	$4.42M	Sell	632,745 -934,150	-60%	-$9.08M	1.18%	13
2022 Q1	$23.7M	Buy	1,566,895 +15,825	+1%	+$249K	5.12%	4
2021 Q4	$34M	Buy	1,551,070 +719,803	+87%	+$17.6M	6.62%	4
2021 Q3	$22.4M	Hold	831,267	–	–	5.52%	6
2021 Q2	$20M	Buy	831,267 +452,979	+120%	+$13.9M	4.15%	6
2021 Q1	$16.4M	Buy	378,288 +511	+0.1%	+$22.6K	6.18%	4
2020 Q4	$15.7M	Buy	+377,777	New	+$15.6M	5.43%	5

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Octagon Capital Advisors's FDMT Position: Q2 2023 in Review

Octagon Capital Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q2 2023, closing a stake of 499,996 shares — an estimated $8.59M sold.

Octagon Capital Advisors first reported a position in FDMT in Q4 2020 and held it in 10 quarters. The position peaked at $34M in Q4 2021. 100 funds tracked by Wall St. Rank hold FDMT as of Q2 2023.

Octagon Capital Advisors reported no remaining 4D Molecular Therapeutics position as of Q2 2023 after selling out during the quarter.
Octagon Capital Advisors sold 499,996 4D Molecular Therapeutics shares in Q2 2023, an estimated $8.59M.
Octagon Capital Advisors first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 10 quarters.
Octagon Capital Advisors's 4D Molecular Therapeutics position peaked at $34M in Q4 2021.
100 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2023.

Based on Octagon Capital Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.